Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience

References

• CabanillasME, McFaddenDG, DuranteC. Thyroid cancer. Lancet. 2016;388(10061):2783–2795. doi:10.1016/S0140-6736(16)30172-627240885
   PubMed Web of Science ®Google Scholar
• TamaiT, HayatoS, HojoS, et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 2017;57(9):1138–1147. doi:10.1002/jcph.91728561918
   PubMed Web of Science ®Google Scholar
• HaugenBR, ShermanSI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013;34(3):439–455. doi:10.1210/er.2012-103823575762
   PubMed Web of Science ®Google Scholar
• SchmidbauerB, MenhartK, HellwigD, GrosseJ. Differentiated thyroid cancer—treatment: state of the art. Int J Mol Sci. 2017;18(6):1292. doi:10.3390/ijms18061292
   PubMed Web of Science ®Google Scholar
• PaciniF. Which patient with thyroid cancer deserves systemic therapy and when?Best Pract Res Clin Endocrinol Metab. 2017;31(3):291–294. doi:10.1016/j.beem.2017.08.00128911725
   PubMed Web of Science ®Google Scholar
• BerdelouA, LamartinaL, KlainM, LeboulleuxS, SchlumbergerM. Treatment of refractory thyroid cancer. Endocr Relat Cancer. 2018;25(4):R209–R223. doi:10.1530/ERC-17-054229371330
   PubMed Web of Science ®Google Scholar
• CabanillasME, HabraMA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016;42:47–55. doi:10.1016/j.ctrv.2015.11.00326678514
   PubMed Web of Science ®Google Scholar
• SchlumbergerM, TaharaM, WirthLJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi:10.1056/NEJMoa140647025671254
   PubMed Web of Science ®Google Scholar
• CostaR, CarneiroBA, ChandraS, et al. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther. 2016;10:873–884. doi:10.2147/DDDT.S93459
   PubMed Web of Science ®Google Scholar
• NairA, LemerySJ, YangJ, et al. FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2015;21(23):5205–5208. doi:10.1158/1078-0432.CCR-15-137726324740
   PubMed Web of Science ®Google Scholar
• FerrariSM, RuffilliI, CentanniM, et al. Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent Pat Anticancer Drug Discov. 2018;13(2):201–208. doi:10.2174/157489281366618022011072929468981
   PubMed Web of Science ®Google Scholar
• BerdelouA, BorgetI, GodbertY, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid. 2018;28(1):72–78. doi:10.1089/thy.2017.020529048237
   PubMed Web of Science ®Google Scholar
• KiyotaN, SchlumbergerM, MuroK, et al. Subgroup analysis of Japanese patients in a Phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015;106(12):1714–1721. doi:10.1111/cas.1282626426092
   PubMed Web of Science ®Google Scholar
• NagahamaM, OzekiT, SuzukiA, et al. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol. 2019;36(5):39. doi:10.1007/s12032-019-1263-330919115
   PubMed Web of Science ®Google Scholar
• BroseMS, NuttingCM, JarzabB, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328. doi:10.1016/S0140-6736(14)60421-924768112
   PubMed Web of Science ®Google Scholar
• YuST, GeJN, LuoJY, WeiZG, SunBH, LeiST. Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis. Cancer Manag Res. 2019;11:1525–1532. doi:10.2147/cmar.s19149930863162
   PubMed Web of Science ®Google Scholar
• CapdevilaJ, NewboldK, LicitraL, et al. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev. 2018;69:164–176. doi:10.1016/j.ctrv.2018.06.01930032061
   PubMed Web of Science ®Google Scholar
• IwasakiH, YamazakiH, TakasakiH, et al. Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. Oncol Lett. 2019;17(6):5292–5300. doi:10.3892/ol.2019.1018031186746
   PubMed Web of Science ®Google Scholar
• YamazakiH, IwasakiH, TakasakiH, et al. Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer. Medicine. 2019;98(10):e14774. doi:10.1097/md.000000000001477430855484
   PubMed Web of Science ®Google Scholar
• RobinsonB, SchlumbergerM, WirthLJ, et al. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab. 2016;101(11):4103–4109. doi:10.1210/jc.2015-398927548104
   PubMed Web of Science ®Google Scholar
• TaharaM, BroseMS, WirthLJ, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019;106:61–68. doi:10.1016/j.ejca.2018.10.00230471649
   PubMed Web of Science ®Google Scholar
• YunKJ, KimW, KimEH, et al. Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer. Endocrinol Metab. 2014;29(3):388–393. doi:10.3803/EnM.2014.29.3.388
   Google Scholar
• UchidaT, YamaguchiH, NagamineK, et al. Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer. Endocrinol Diabetes Metab Case Rep. Epub 2019 Mar 18. doi:10.1530/EDM-18-0158
   Google Scholar
• MarkmanM. Lenvatinib real-life experience. Oncology. 2019;97(4):189–191. doi:10.1159/00050164131390640
   PubMed Web of Science ®Google Scholar
• MancusoMR, DavisR, NorbergSM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116(10):2610–2621. doi:10.1172/JCI2461217016557
   PubMed Web of Science ®Google Scholar
• MatroneA, ValerioL, PieruzziL, et al. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: from the clinical trials to the real life. Best Pract Res Clin Endocrinol Metab. 2017;31(3):319–334. doi:10.1016/j.beem.2017.06.00128911728
   PubMed Web of Science ®Google Scholar
• ViolaD, ValerioL, MolinaroE, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23(4):R185–R205. doi:10.1530/ERC-15-055527207700
   PubMed Web of Science ®Google Scholar
• LeeEK, KimS-M, KimBH, et al. Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: a Korean multicenter retrospective study. Thyroid. 2019;29(12):1811–1819. doi:10.1089/thy.2019.002231482759
   PubMed Web of Science ®Google Scholar
• SuzukiC, KiyotaN, ImamuraY, et al. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head Neck. 2019;41(9):3023–3032. doi:10.1002/hed.2578431013380
   PubMed Web of Science ®Google Scholar
• GianoukakisAG, DutcusCE, BattyN, GuoM, BaigM. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer. 2018;25(6):699–704. doi:10.1530/erc-18-004929752332
   PubMed Web of Science ®Google Scholar
• KiyotaN, RobinsonB, ShahM, et al. Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT TRIAL. Thyroid. 2017;27(9):1135–1141. doi:10.1089/thy.2016.054928665259
   PubMed Web of Science ®Google Scholar
• TuttleRM, BroseMS, GrandeE, KimSW, TaharaM, SabraMM. Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2017;31(3):295–305. doi:10.1016/j.beem.2017.04.01428911726
   PubMed Web of Science ®Google Scholar